Literature DB >> 10744589

Interactions between apolipoprotein E and apolipoprotein(a) in patients with late-onset Alzheimer disease.

V Mooser1, N Helbecque, J Miklossy, S M Marcovina, P Nicod, P Amouyel.   

Abstract

BACKGROUND: Apolipoprotein(a) [apo(a)], the distinctive, highly polymorphic glycoprotein of lipoprotein(a), shares a series of common features with apolipoprotein E (apoE), which is implicated in the development of Alzheimer disease.
OBJECTIVE: To determine whether apo(a) is associated with Alzheimer disease.
DESIGN: Case-control study.
SETTING: University hospitals in Europe. PARTICIPANTS: 285 patients with Alzheimer disease and 296 controls. MEASUREMENTS: Plasma lipoprotein(a) levels, size of the apo(a) isoforms, and apoE and apo(a) genotyping.
RESULTS: Among carriers of the apoE epsilon4 allele, lipoprotein(a) was associated with a progressive, age-dependent increased risk for late-onset Alzheimer disease (odds ratio for patients >80 years of age, 6.0 [95% CI, 1.2 to 30.8]; P<0.01). Among noncarriers older than 80 years of age, lipoprotein(a) was associated with a reduced risk for Alzheimer disease (odds ratio, 0.4 [CI, 0.2 to 0.91; P<0.05).
CONCLUSIONS: In this convenience sample, lipoprotein(a) was an additional risk factor for late-onset Alzheimer disease in carriers of the apoE epsilon4 allele. However, lipoprotein(a) may protect against late-onset Alzheimer disease in noncarriers.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10744589     DOI: 10.7326/0003-4819-132-7-200004040-00004

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  8 in total

1.  Is lipoprotein (a) protective of dementia?

Authors:  Setor K Kunutsor; Hassan Khan; Kristiina Nyyssönen; Jari A Laukkanen
Journal:  Eur J Epidemiol       Date:  2016-07-13       Impact factor: 8.082

2.  Lipoprotein(a), apolipoprotein E genotype, and risk of Alzheimer's disease.

Authors:  V Solfrizzi; F Panza; A D'Introno; A M Colacicco; C Capurso; A M Basile; A Capurso
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-06       Impact factor: 10.154

3.  Plasma apolipoprotein(a) co-deposits with fibrin in inflammatory arthritic joints.

Authors:  N Busso; J Dudler; R Salvi; V Péclat; V Lenain; S Marcovina; R Darioli; P Nicod; A K So; V Mooser
Journal:  Am J Pathol       Date:  2001-10       Impact factor: 4.307

4.  Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes.

Authors:  Judith Miklossy; Hong Qing; Aleksandra Radenovic; Andras Kis; Bertrand Vileno; Forró Làszló; Lisa Miller; Ralph N Martins; Gerard Waeber; Vincent Mooser; Fred Bosman; Kamel Khalili; Nune Darbinian; Patrick L McGeer
Journal:  Neurobiol Aging       Date:  2008-10-23       Impact factor: 4.673

5.  Alzheimer's disease.

Authors:  A S Schachter; K L Davis
Journal:  Dialogues Clin Neurosci       Date:  2000-06       Impact factor: 5.986

6.  Lipoprotein profile in older patients with vascular dementia and Alzheimer's disease.

Authors:  G Zuliani; A Ble'; R Zanca; M R Munari; A Zurlo; C Vavalle; A R Atti; R Fellin
Journal:  BMC Geriatr       Date:  2001       Impact factor: 3.921

7.  Relationship between Lipoprotein (a) and cognitive function - Results from the Berlin Aging Study II.

Authors:  Nikolaus Buchmann; Sandra Düzel; Franziska Röhr; Nina Bucholtz; Sarah Toepfer; Kristina Norman; Dominik Spira; Elisabeth Steinhagen-Thiessen; Christina M Lill; Lars Bertram; Ilja Demuth
Journal:  Sci Rep       Date:  2020-06-30       Impact factor: 4.379

Review 8.  Vascular risk factors, cognitive decline, and dementia.

Authors:  E Duron; Olivier Hanon
Journal:  Vasc Health Risk Manag       Date:  2008
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.